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We have recently shown that in childhood acute lymphoblastic 
leukemia (ALL) blasts at different stages of immunophenotypic 
maturation possess stem cell properties. Here, we discuss our 
results in the context of previous investigations of ALL stem 
cells and recent studies highlighting specific limitations of the 
xenotransplantation models for human hematopoietic cells. 
Leukemia-propagating stem cells in ALL may be more frequent 
than previously thought!
Although the concept of a malignant cancer stem cell has 
been around for several decades,1 the first experimental evidence 
for rare cancer stem cells maintaining human leukemia is based 
on xenotransplantation studies pioneered in the early nineties in 
Dick’s laboratory in Toronto.2,3 In this model, only rare human 
AML cells with an immunophenotype resembling that of normal 
hematopoietic stem cells, i.e., CD34+CD38- blasts, were able to 
transfer the leukemia onto immune deficient SCID mice. Based on 
these experiments, many subsequent xenotransplantation studies 
have described rare cancer stem cell populations in a variety of 
leukemias and cancers.1 To distinguish cancer maintaining stem 
cells from the cell or origin in which the malignancy originally 
arose, cancer stem cells have been defined by their extensive 
proliferation potential, their ability to self-renew and their differ-
entiation potential, i.e., their “capacity to cause the heterogeneous 
lineages of cancer cells that comprise the tumor”.4
Indeed several studies had suggested that this stem cell hier-
archy could also be applied to childhood ALL.5-7 First, Cobaleda 
and co-workers had shown that only primitive blasts with a 
CD34+CD38- immunophenotype were able to transfer BCR/
ABL-positive ALL onto immune deficient NOD scid mice.5 These 
data were confirmed by Blair’s group in Bristol which showed that 
for a variety of ALL only CD34+ blasts that lacked expression 
of lymphoid antigens (CD10 and CD19) but expressed CD133 
were able to proliferate long-term in immune deficient mice.6,8 
Finally in an excellent study modeling the origin of TEL/AML1-
positive ALL, Enver, Greaves and co-workers demonstrated that 
transduction of TEL/AML1 into human cord blood produces an 
abnormal CD34+CD19+CD38- candidate (pre-)leukemic stem 
cell population. Using samples from 3 patients with TEL/AML1-
positive ALL, only these candidate CD34+CD19+CD38- cells were 
able to engraft primary and secondary NOD scid mice at levels 
ranging from 0.5–8% human cells in the murine bone marrow, 
while transplantation of CD34+CD19+CD38+ cells from only one 
of the 3 patients led to low levels (0.3%) of human engraftment 
in primary but not secondary mice.7 In conclusion, evidence was 
accumulating that the situation in ALL would be very similar to 
AML and normal hematopoiesis with a specialized subpopulation 
of rare leukemic stem cells maintaining the malignant clone.
With this concept in mind, we started to separate different 
subpopulations in childhood B cell precursor ALL based on the 
expression of the lymphoid differentiation markers CD19, CD20 
and CD34. While we have had no difficulties in reproducing the 
original work by Kamel-Reid from Dick’s laboratory9,10 and easily 
engrafted non-manipulated primary ALL in scid mice11 we were 
struggling to engraft flow sorted ALL cells. Our hypothesis on our 
inability to engraft ex vivo manipulated blast populations was based 
on the propensity of ALL cells to undergo apoptosis in vitro. By 
thawing and flow sorting we thought we might be loosing many of 
the viable leukemic stem cells. Therefore, we attempted to optimize 
both the viability of the samples and the sensitivity of our assay:
•	 Firstly,	 we	 decided	 to	 transplant	 the	 limited	 patient	
material after thawing directly and without any additional ex 
vivo manipulation onto primary mice. We then used mainly fresh 
leukemic cells recovered from engrafted mice for flow sorting 
and subsequent transplantations. This also allows amplification 
of precious samples from children with ALL with often limited 
numbers of cells. (In retrospect, this point seems to be of limited 
relevance as primary sorted cells engraft well in the optimized 
mouse model).
•	 Secondly,	 new	 advances	 in	 the	 xenograft	 models	 had	
become available and, therefore, we adapted our transplantation 
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protocol by using either NOD scid mice pre-treated with an anti-
CD122 anti-NK cell antibody12 and more recently NOD scid 
gamma (NSG) mice (Jax® mice stock name: NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ)13 as recipients. Both xenotransplant approaches 
represent more sensitive models for human hematopoietic cells.
•	 Thirdly,	it	had	been	shown	that	intrafemoral	injection	of	
candidate stem cells leads to an approximately tenfold more sensi-
tive	stem	cell	assay	as	compared	with	intravenous	injection.14
•	 Finally,	we	used	non-irradiated	mice	as	recipients	as	our	
previous work had shown that ALL (unlike normal hematopoietic 
cells or leukemias of myeloid lineage) engraft non-conditioned 
immune deficient mice as well as irradiated mice.11 Lapidot from 
the Weizmann Institute in Israel had shown that ALL progeni-
tors respond differently to stromal cell-derived factor 1 (SDF-1) 
compared with normal progenitors.15 In particular, a significant 
reduction of ALL cells was observed in irradiated murine bone 
marrow,	16	hours	after	injection;	therefore,	upregulation	of	SDF-1	
in the murine bone marrow following total body irradiation may 
impair ALL engraftment.
To our big surprise, using this optimized experimental xeno-
transplantation protocol, every population we purified, i.e., 
CD34+CD19-, CD34+CD19+ and CD34-CD19+ blasts, was able 
to transfer the leukemia onto primary, secondary and tertiary 
recipients. In addition, each population also gave rise to all other 
populations present in the original leukemia and was, therefore, 
able to reconstitute the complete ALL immunophenotype.
To exclude contamination of the more mature populations by 
rare primitive stem cells we performed extensive purity checks 
and limiting dilution experiments. We showed that the level of 
potentially contaminating blasts from other populations was well 
below the limit of engraftment when mice were transplanted at 
low cell doses (as few as 2,000 flow sorted cells). To exclude that 
we were creating an in vivo cell line through passage of the human 
cells in the mice resulting in an altered stem cell hierarchy, we also 
transplanted primary sorted cells and got similar results.16 This has 
been confirmed by additional experiments. Overall, we have so far 
successfully engrafted 25 primary mice with sorted cells from 5 
different patients and all populations engrafted in this optimized 
mouse model.
Finally, we examined the maturation state of the different 
populations in more detail. Gene expression studies (expression 
arrays and real-time RT-PCR) demonstrated that the immu-
nophenotypically more immature CD34+CD19+ cells and the 
immunophenotypically more mature CD34-CD19+ also differed 
at the level of RNA expression. In particular, the more mature 
CD34- population expressed the later B cell differentiation factor 
IRF4, several immunoglobulin genes and CD20, whilst CD34 
expression was downregulated. Thereby, we demonstrated that the 
observed engraftment of the different populations was not solely 
based on modulation of individual markers at the cell surface. The 
different populations represent blasts at different levels of B cell 
maturation.
These data informed a new stem cell model for childhood 
ALL.16 All populations—immunophenotypically more immature 
as well as more mature populations—were able to re-establish 
the complete ALL immunophenotype in the mice, consisting of 
all populations present in the original leukemia. This indicated 
that the blasts are able to go back and forth within a very limited 
window of B cell maturation (malleability).
We speculate that the leukemic blasts acquire this malleability 
if they are not positively selected to continue differentiation (e.g., 
by the lack of expression of a functional pre-B cell receptor) but 
unlike normal B precursors do not die of apoptosis (presumably 
due to a disturbed apoptosis program). This ability of the cells 
to go back and forth was called malleability, in distinction to 
plasticity which would imply that the ALL blasts were able to 
transdifferentiate into other lineages, e.g., myeloid, a phenomenon 
not observed in our studies.
Very recent studies by Ishikawa and his group in Fukuoka, 
Japan, made similar observations and showed that indeed 
both CD34+CD19+CD38- and CD34+CD19+CD38+ cells in 
MLL-AF4-positive infant leukemia can propagate the leukaemia 
in NSG mice.17 Most importantly, work from Civin’s group as 
reported at the 2009 American Society of Hematology meeting in 
San Francisco showed a high frequency of ALL stem cells supporting 
this model: limiting dilution experiments with unsorted primary 
cells demonstrated that in some patients as few as 10 primary ALL 
cells were able to initiate the leukemia in immune deficient NSG 
mice	following	intravenous	transplantation	(Blood	2008;	112:487,	
abstract #1354). Therefore, evidence is accumulating that at least 
in some lymphoid leukemias blasts with self-renewing capability 
may exist at much higher frequency than previously thought and 
most, if not all, ALL blasts may possess stem cell properties.
These data fuel a recent debate over whether the stem concept is 
applicable to all human cancers and whether some of the xenograft 
models are misleading and underestimate the frequency of the cells 
that can propagate leukemia and cancer.18 A recent publication 
from Bonnet’s group at the London Research Institute has shown 
that human cells coated with several anti-CD38 antibodies (CD38 
HIT2 IgG1κ, CD38 HB7 IgG1κ, CD38 AT13/5 IgG1κ) can be 
cleared in immune deficient mice.19 These data suggest that many 
previous xenotransplantation studies may need to be revisited, 
including previous ALL studies.5,7 Fortunately, we had not used 
CD38 as a selection marker and pre-treatment of the recipient 
mice with the anti-CD122 antibody or the use of the more 
immune-deficient	NSG	mice	 and	 intrafemoral	 injection	protects	
against in vivo clearance of antibody-coated human cells.19
What can we learn from these studies? Although this picture 
may change with the use of the new optimized xenotransplanta-
tion protocols, for a long time it has been observed that not all 
leukemias engraft immune deficient mice (see Table 1). The mech-
anisms for this failure to engraft remain unclear.20 These data in 
their own right should have taught us that not every cell that fails 
to engraft a xenograft host automatically lacks stemness. There are 
many potential reasons for non-engraftment (see Table 2).
Is the stem cell concept dead for ALL? Additional studies are 
needed to test the stem cell frequency in a more comprehensive 
cohort of patients with ALL and at present we cannot exclude 
that there may be heterogeneity in the stem cell hierarchy between 
different ALL subtypes. Most importantly, more studies are needed 
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 primitive CD34+CD19- compartment25 and this was confirmed in 
our recent study.16 Primitive CD34+CD19- stem cell populations 
in high risk ALL may express drug resistance genes usually present 
in multipotent hematopoietic stem cells (e.g., MDR and other 
ABC transporter genes). In addition, there may be heterogeneity 
in the expression of survival genes, cell cycle regulation or niche 
requirements between the different blast populations. Finally, 
the stem cell program in lymphoid leukemias may be different 
from that of normal multipotent hematopoietic stem cells—more 
similar to mature B and T lymphocytes—and provide novel targets 
for more specific therapies.
In conclusion, these data indicate a paradigm shift in our 
thinking about stem cells in childhood ALL: from a rare, to almost 
every, cell within the leukemic clone! However, we are only at the 
beginning of understanding the biology of how these blasts self-
renew and propagate the leukemia. The challenge for the next few 
years will be to unravel the biology of leukemic stem cells in child-
hood ALL with the goal to utilize the differences between the stem 
cell program in ALL blasts and in normal hematopoietic stem cells 
as targets for novel and more specific therapies. Only if we succeed 
will we be able to prove the clinical relevance of the concept of 
leukemic stem cells in ALL.
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